IN8bio posts corporate deck highlighting gamma-delta T-cell therapy platform for autoimmune disease, cancer

In8bio

INAB

0.00

IN8bio outlined a gamma-delta T cell platform spanning autoimmune disease and oncology, highlighting no serious side effects observed to date.
Pipeline focus includes T cell engagers, with IND-enabling studies supported by initial mouse-model data expected in 2026.
Cell therapy program in AML targets completion of dosing in an additional DL2 expansion cohort in 2026, with updates and follow-up by year-end 2026.
First-line glioblastoma program is completed, with a peer-reviewed publication planned and FDA discussions on potential registrational paths targeted in 2026.
Presentation flagged mid- and late-2026 updates for overall survival data in glioblastoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.